Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
      Description

      Open-label, Phase 2, single treatment arm, 3 cohorts

      Conditions
      NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIICNSCLC, RecurrentEGFR Exon 20 Insertion MutationHER2-activating MutationERBB FusionNRG1 Fusion
      Talk to us